ArticleInternational journal of hepatology2012
A current review of the diagnostic and treatment strategies of hepatic encephalopathy.
Article in International journal of hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Probiotics for people with hepatic encephalopathy.The Cochrane database of systematic reviews · 2017Pooled it
- Effects of shunt embolization on hepatic encephalopathy recurrence in patients with major portosystemic shunts: A systematic review and meta‑analysis.Biomedical reports · 2025Article
- Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy.World journal of hepatology · 2024Article
- Inadequate practices for hepatic encephalopathy management in the inpatient setting.Journal of hospital medicine · 2022Review
- Protective effect of probiotics and ascorbic acid on bile duct ligation-induced chronic hepatic encephalopathy in rats.Research in pharmaceutical sciences · 2022Article
- Metabolomics profiles in acute-on-chronic liver failure: Unveiling pathogenesis and predicting progression.Frontiers in pharmacology · 2022Review
- Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation.Journal of clinical medicine · 2021Review
- Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.Journal of hepatology · 2021Review
- The Association between Hepatic Encephalopathy and Diabetic Encephalopathy: The Brain-Liver Axis.International journal of molecular sciences · 2021Review
- Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management.Frontiers in medicine · 2021Review
- Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy.Digestive diseases and sciences · 2020Review
- Sarcopenia: Ammonia metabolism and hepatic encephalopathy.Clinical and molecular hepatology · 2019Review
- L-Ornithine L-Aspartate is Effective and Safe for the Treatment of Hepatic Encephalopathy in Cirrhosis.Journal of clinical and experimental hepatology · 2018Article
- Update on the Therapeutic Management of Hepatic Encephalopathy.Current gastroenterology reports · 2018Review
- Hepatic encephalopathy: a critical current review.Hepatology international · 2018Review
- Hepatic encephalopathy: current challenges and future prospects.Hepatic medicine : evidence and research · 2018Review
- Limonene in exhaled breath is elevated in hepatic encephalopathy.Journal of breath research · 2016Article
- Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions.Gut and liver · 2016Review
- Effect of undifferentiated versus hepatogenic partially differentiated mesenchymal stem cells on hepatic and cognitive functions in liver cirrhosis.EXCLI journal · 2016Article
- Therapy of hyperammonemia.EXCLI journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a serious and potentially fatal complication in patients with cirrhotic liver disease. It is a spectrum ranging from minimal hepatic encephalopathy (MHE) without recognizable clinical symptoms or signs, to overt HE with risk of cerebral edema and death. HE results in diminished quality of life and survival. The broad range of neuropsychiatric manifestations reflects the range of pathophysiological mechanisms and impairment in neurotransmission that are purported to cause HE including hyperammonemia, astrocyte swelling, intra-astrocytic glutamine, upregulation of 18-kDa translocator protein (TSPO) (formerly known as peripheral benzodiazepine receptor or PBTR), and manganese. There is a myriad of diagnostic tools including simple bedside clinical assessment, and more complex neuropsychological batteries and neurophysiological tests available today. Current treatment strategies are directed at reducing ammonia, with newer agents showing some early promise. This paper describes the pathophysiology of the disease and summarises current diagnostic and treatment therapies available.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.